Values as of: 2025-06-15
COMMON STOCK | Biotechnology |
Last Closing
USD 0.0001Change
0.00 (0.00)%Market Cap
USD 0.07BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.
Company Website : https://bonus-bio.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| UCBJF | UCB SA |
N/A |
USD 37.40B |
| ARGNF | argenx SE |
N/A |
USD 34.32B |
| UCBJY | UCB SA ADR |
N/A |
USD 33.77B |
| IVBIY | IVBIY |
N/A |
USD 16.84B |
| GNMSF | Genmab A/S |
N/A |
USD 14.10B |
| WXIBF | WuXi Biologics |
N/A |
USD 12.07B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 12.07B |
| AKESF | Akeso, Inc. |
N/A |
USD 9.60B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 9.28B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 8.94B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -99.50% | 3% | F | 1% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -99.50% | 3% | F | 1% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -99.75% | 4% | F | 1% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -99.75% | 4% | F | 1% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -99.92% | 14% | F | 4% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -99.92% | 14% | F | 4% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 750.03% | 90% | A- | 95% | A | ||
| Dividend Return | 750.03% | 90% | A- | 95% | A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 3,027.56% | 12% | F | 5% | F | ||
| Risk Adjusted Return | 24.77% | 83% | B | 66% | D+ | ||
| Market Capitalization | 0.07B | 72% | C | 55% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
